Schwab Charles Investment Management Inc. grew its position in BioTelemetry, Inc. (NASDAQ:BEAT) by 11.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 140,634 shares of the medical research company’s stock after purchasing an additional 13,962 shares during the period. Schwab Charles Investment Management Inc.’s holdings in BioTelemetry were worth $4,205,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. FNY Partners Fund LP increased its stake in shares of BioTelemetry by 74.1% in the 3rd quarter. FNY Partners Fund LP now owns 7,000 shares of the medical research company’s stock valued at $231,000 after buying an additional 2,980 shares during the period. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of BioTelemetry in the 3rd quarter valued at $232,000. Premier Asset Management LLC acquired a new stake in shares of BioTelemetry in the 3rd quarter valued at $237,000. Macquarie Group Ltd. acquired a new stake in shares of BioTelemetry in the 3rd quarter valued at $279,000. Finally, Quantbot Technologies LP increased its stake in shares of BioTelemetry by 577.1% in the 3rd quarter. Quantbot Technologies LP now owns 9,087 shares of the medical research company’s stock valued at $299,000 after buying an additional 7,745 shares during the period. 87.49% of the stock is owned by institutional investors.
In other BioTelemetry news, insider Fred Broadway sold 54,158 shares of the business’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $34.17, for a total value of $1,850,578.86. Following the completion of the transaction, the insider now directly owns 64,880 shares of the company’s stock, valued at $2,216,949.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 9.60% of the stock is currently owned by insiders.
Shares of BioTelemetry, Inc. (NASDAQ:BEAT) opened at $33.45 on Friday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 1.66 and a current ratio of 1.77. BioTelemetry, Inc. has a 52 week low of $23.30 and a 52 week high of $39.20. The company has a market capitalization of $1,088.16, a price-to-earnings ratio of 38.45, a P/E/G ratio of 1.65 and a beta of 0.75.
BioTelemetry (NASDAQ:BEAT) last announced its quarterly earnings data on Thursday, February 22nd. The medical research company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.24 by $0.08. BioTelemetry had a positive return on equity of 14.54% and a negative net margin of 5.56%. The business had revenue of $91.70 million during the quarter, compared to analysts’ expectations of $88.33 million. During the same period in the previous year, the firm earned $0.23 earnings per share. The firm’s quarterly revenue was up 69.8% compared to the same quarter last year. analysts anticipate that BioTelemetry, Inc. will post 1.28 EPS for the current year.
A number of equities research analysts recently commented on the company. BidaskClub cut BioTelemetry from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research raised BioTelemetry from a “strong sell” rating to a “hold” rating in a research note on Monday, January 22nd. Finally, Dougherty & Co reaffirmed a “buy” rating and set a $41.00 price objective (up from $40.00) on shares of BioTelemetry in a research note on Friday, February 23rd. Two analysts have rated the stock with a sell rating and seven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $43.00.
ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/18/schwab-charles-investment-management-inc-grows-stake-in-biotelemetry-inc-beat.html.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Want to see what other hedge funds are holding BEAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTelemetry, Inc. (NASDAQ:BEAT).
Receive News & Ratings for BioTelemetry Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry and related companies with MarketBeat.com's FREE daily email newsletter.